Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.
A simple blood sample
DiviTum® is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum® biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.
New unique data from US breast cancer congress
The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum® measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum® may thus serve as a non-invasive marker and early response indicator of the anti-proliferative effect of CDK4/6 inhibitors like palbociclib.
Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.
Biovica to present at Stora Aktiedagen focused on Life Science, held in Lund the 29th of January 2019
Uppsala, January 23, 2019. Biovica will present at Stora Aktiedagen focused on Life Science, a small-cap investor conference, held on January 29, 2019 at Medicon Village, Scheelevägen 2 in Lund. The event is arranged by Aktiespararna and the company will be represented by CEO Anders Rylander 12.50 CET.
Uppsala, Sweden, January 21, 2019. Mattias Bergqvist, Biovica, is invited to give an oral presentation at the 14th Annual Biomarkers Congress 21-22 February 2019, Manchester, UK.
Biovica opens an office in Boston, the first office in the US. Pontus Nobréus, Business Development Director, will be heading up the office and will be based in Boston from 1st of January 2019.
BEST POSSIBLE TREATMENT FROM DAY ONE
Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum® biomarker assay, aim to increase survival and improve quality of life.
Clinical trials and Collaborations
Biovica has successfully worked to realize its vision for Divitum® by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).